EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer

Hyewon Lee iD, Jung Yoon Ho, In Sun Hwang, Youn Jin Choi

FEBS Open Bio · 2026

DOI: 10.1002/2211-5463.70126 ↗

Kurz gefasst

Fachartikel in der Zeitschrift FEBS Open Bio, 2026. Verfasst von Hyewon Lee und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Hauptthemen laut MEDLINE: Indoleamine-Pyrrole 2,3,-Dioxygenase, Ovarian Neoplasms, Cancer-Associated Fibroblasts, Cystadenocarcinoma, Serous. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul St. Mary's Hospital, The Catholic University of Korea, Korea Research Foundation for Gynecologic Cancer, Seoul St. Mary's Hospital, Catholic University of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer‐associated fibroblasts (CAFs) contribute to immunosuppression in the ovarian cancer microenvironment, partly through upregulation of indoleamine 2,3‐dioxygenase 1 (IDO1). This study examined CAF‐mediated suppression of T‐cell function and the potential of IDO1 inhibition to reverse these effects. CAFs from high‐grade serous ovarian cancer (HGSOC) patients exhibited increased IDO1, COX2, and PD‐L1 expression upon interaction with activated T cells, along with elevated immunosuppressive cytokines. CAFs suppressed T‐cell proliferation and induced PD‐1 expression in CD4+ and CD8+ T cells, effects reversed by epacadostat. IDO1 inhibition enhanced T‐cell proliferation via AKT signaling, restored T‐cell cytotoxicity, and increased ovarian cancer cell apoptosis. These findings suggest that targeting IDO1 may help counteract CAF‐mediated immunosuppression and enhance antitumor immunity in HGSOC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Indoleamine-Pyrrole 2,3,-DioxygenaseOvarian NeoplasmsCancer-Associated FibroblastsCystadenocarcinoma, SerousHumansFemaleTumor MicroenvironmentCell ProliferationCell Line, TumorApoptosisImmune ToleranceT-Lymphocytes

Stichwörter der Autor:innen

IDO1cancer‐associated fibroblastsimmunosuppressionovarian cancertumor microenvironment

Substanzen

Indoleamine-Pyrrole 2,3,-DioxygenaseIDO1 protein, human

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.

ORCID-Profile: Hyewon Lee

Förderung

  • Seoul St. Mary's Hospital, The Catholic University of Korea
  • Korea Research Foundation for Gynecologic Cancer
  • Seoul St. Mary's Hospital, Catholic University of Korea

Zitieren

APA

Lee, H., Ho, J. Y., Hwang, I. S., & Choi, Y. J. (2026). Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer. FEBS Open Bio. https://doi.org/10.1002/2211-5463.70126

Vancouver

Lee H, Ho JY, Hwang IS, Choi YJ. Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer. FEBS Open Bio. 2026. doi:10.1002/2211-5463.70126

BibTeX
@article{Lee2026,
  author = {Lee, Hyewon and Ho, Jung Yoon and Hwang, In Sun and Choi, Youn Jin},
  title = {Indoleamine 2,3‐dioxygenase 1 inhibition reverses cancer‐associated fibroblast‐mediated immunosuppression in high‐grade serous ovarian cancer},
  journal = {FEBS Open Bio},
  year = {2026},
  doi = {10.1002/2211-5463.70126}
}
Kostenlos starten →